Ignite Creation Date:
2025-12-25 @ 2:05 AM
Ignite Modification Date:
2026-05-13 @ 10:14 PM
Study NCT ID:
NCT05442060
Status:
RECRUITING
Last Update Posted:
2025-08-03
First Post:
2022-06-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor:
OBI Pharma, Inc
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
OBI-833-003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None